Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24

Reuters01:30

Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24

Alumis reported Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.
Data were already presented as a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting.
Week 24 PASI 90 reached 68.0% in ONWARD1, 62.1% in ONWARD2, up from 59.9% and 53.1% at Week 16.
Complete clearance (PASI 100) rose to 41.0% and 39.5% at Week 24, up from 29.4% and 27.7% at Week 16.
Alumis targets a US FDA New Drug Application submission in second half of 2026, positioning envudeucitinib as a potential leading oral option in plaque psoriasis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281330PRIMZONEFULLFEED9680250) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623872173?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 01:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623872173","market":"fut","top_or_hot":-1,"title":"Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alumis reported Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.\n        </li>\n<li>\n          Data were already presented as a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          Week 24 PASI 90 reached 68.0% in ONWARD1, 62.1% in ONWARD2, up from 59.9% and 53.1% at Week 16.\n        </li>\n<li>\n          Complete clearance (PASI 100) rose to 41.0% and 39.5% at Week 24, up from 29.4% and 27.7% at Week 16.\n        </li>\n<li>\n          Alumis targets a US FDA New Drug Application submission in second half of 2026, positioning envudeucitinib as a potential leading oral option in plaque psoriasis.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281330PRIMZONEFULLFEED9680250) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-29 01:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alumis reported Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.\n        </li>\n<li>\n          Data were already presented as a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          Week 24 PASI 90 reached 68.0% in ONWARD1, 62.1% in ONWARD2, up from 59.9% and 53.1% at Week 16.\n        </li>\n<li>\n          Complete clearance (PASI 100) rose to 41.0% and 39.5% at Week 24, up from 29.4% and 27.7% at Week 16.\n        </li>\n<li>\n          Alumis targets a US FDA New Drug Application submission in second half of 2026, positioning envudeucitinib as a potential leading oral option in plaque psoriasis.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281330PRIMZONEFULLFEED9680250) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL1Hr964:1","article_id":"2623872173","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623872173","pubTimestamp":1774719015,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alumis reported Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.Data were already presented as a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting.Week 24 PASI 90 reached 68.0% in ONWARD1, 62.1% in ONWARD2, up from 59.9% and 53.1% at Week 16.Complete clearance  rose to 41.0% and 39.5% at Week 24, up from 29.4% and 27.7% at Week 16.Alumis targets a US FDA New Drug Application submission in second half of 2026, positioning envudeucitinib as a potential leading oral option in plaque psoriasis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据","ALMS":"Alumis Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4007":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Alumis表示，3期试验显示envudeucitinib可在第24周提高银屑病皮肤清除率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ALMS":0.9},"content_text":"Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24\n    \n\n\n          Alumis reported Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.\n        \n\n          Data were already presented as a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting.\n        \n\n          Week 24 PASI 90 reached 68.0% in ONWARD1, 62.1% in ONWARD2, up from 59.9% and 53.1% at Week 16.\n        \n\n          Complete clearance (PASI 100) rose to 41.0% and 39.5% at Week 24, up from 29.4% and 27.7% at Week 16.\n        \n\n          Alumis targets a US FDA New Drug Application submission in second half of 2026, positioning envudeucitinib as a potential leading oral option in plaque psoriasis.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281330PRIMZONEFULLFEED9680250) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623872173","isCrawlerRequest":true}